Co SE (KCO:GR) with a Buy rating and a price target of EUR8.10. The firm's analysts highlight the company's strategic shift towards more promising opportunities in North America and the ...

Please refer to the Universal Registration Document for the year ended December 31, 2023 filed with the Autorité des Marchés Financiers on April 3, 2024 as amended on October 14, 2024 and the Annual ...

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva ... 2023 filed with the Autorité des Marchés Financiers on April 3, 2024 as amended on October 14, 2024 and the Annual ...

Inventiva est une société biopharmaceutique spécialisée dans la recherche et développement de petites molécules administrées par voie orale pour le traitement de patients atteints de la ...

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...

Kepler Cheuvreux’s execution division KCx has expanded its execution access to the Middle East and Northern Africa (MENA). KCx’s expansion opens trading opportunities in the following countries: Dubai ...

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with ...

Kepler Cheuvreux initiated coverage of Rotork (RTOXF) with a Buy rating and 390 GBp price target The firm cites the company’s debt-free balance sheet and strong fundamentals for the Buy rating.

as such estimates are subject to numerous risks including those set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés ...

On Wednesday, Kepler Cheuvreux began covering Kaufman & Broad S.A. (KOF:FP) (OTC: KFMNF) with a Buy rating and set a price target of €39.10. The firm's analysts pointed to the structural trends ...